Rock Springs Capital Management’s Alder Biopharmaceuticals ALDR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-1,300,000
| Closed | -$24.5M | – | 147 |
|
|
2019
Q3 | $24.5M | Sell |
1,300,000
-262,300
| -17% | -$3M | 0.98% | 33 |
|
|
2019
Q2 | $18.4M | Buy |
1,562,300
+2,300
| +0.1% | +$27.8K | 0.67% | 55 |
|
|
2019
Q1 | $21.3M | Buy |
1,560,000
+85,000
| +6% | +$1.1M | 0.82% | 44 |
|
|
2018
Q4 | $15.1M | Sell |
1,475,000
-157,500
| -10% | -$2.02M | 0.71% | 43 |
|
|
2018
Q3 | $27.2M | Buy |
1,632,500
+67,500
| +4% | +$1.22M | 0.98% | 33 |
|
|
2018
Q2 | $24.7M | Buy |
1,565,000
+35,200
| +2% | +$535K | 0.95% | 34 |
|
|
2018
Q1 | $19.4M | Buy |
1,529,800
+474,800
| +45% | +$6.87M | 0.83% | 40 |
|
|
2017
Q4 | $12.1M | Buy |
1,055,000
+180,000
| +21% | +$2.01M | 0.55% | 63 |
|
|
2017
Q3 | $10.7M | Buy |
875,000
+693,000
| +381% | +$7.23M | 0.49% | 69 |
|
|
2017
Q2 | $2.08M | Hold |
182,000
| – | – | 0.11% | 129 |
|
|
2017
Q1 | $3.79M | Hold |
182,000
| – | – | 0.22% | 100 |
|
|
2016
Q4 | $3.79M | Hold |
182,000
| – | – | 0.25% | 88 |
|
|
2016
Q3 | $5.96M | Buy |
182,000
+1,500
| +0.8% | +$45.7K | 0.37% | 78 |
|
|
2016
Q2 | $4.51M | Buy |
180,500
+83,000
| +85% | +$2.25M | 0.33% | 86 |
|
|
2016
Q1 | $2.39M | Buy |
+97,500
| New | +$2.26M | 0.2% | 107 |
|
Rock Springs Capital Management's ALDR Position: Q4 2019 in Review
Rock Springs Capital Management sold out of Alder Biopharmaceuticals (ALDR) in Q4 2019, closing a stake of 1,300,000 shares — an estimated $24.5M sold.
Rock Springs Capital Management first reported a position in ALDR in Q1 2016 and held it in 15 quarters. The position peaked at $27.2M in Q3 2018. 0 funds tracked by Wall St. Rank hold ALDR as of Q4 2019.
- Rock Springs Capital Management reported no remaining Alder Biopharmaceuticals position as of Q4 2019 after selling out during the quarter.
- Rock Springs Capital Management sold 1,300,000 Alder Biopharmaceuticals shares in Q4 2019, an estimated $24.5M.
- Rock Springs Capital Management first reported a position in Alder Biopharmaceuticals in Q1 2016 and held it in 15 quarters.
- Rock Springs Capital Management's Alder Biopharmaceuticals position peaked at $27.2M in Q3 2018.
- 0 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2019.
Based on Rock Springs Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.